SCHEMBL284479

SCHEMBL284479

Cc1ccc(C(N)=O)c(C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
NFE2L2 Q16236 1/20 0.47
NNMT P40261 2/20 0.47
PARP1 P09874 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
KMT2A Q03164 2/20 0.46
HTT P42858 1/20 0.46
HSD11B1 P28845 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
TP53 P04637 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
TNF P01375 1/20 0.44
PKM P14618 1/20 0.44
CDK5 Q00535 1/20 0.44
KLF5 Q13887 1/20 0.44
CDK5R1 Q15078 1/20 0.44
NOD1 Q9Y239 1/20 0.44
SIRT3 Q9NTG7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27585323 0.98 MKNK1 (0.47) MKNK1MKNK2NFE2L2NNMTPARP1
SCHEMBL5679029 0.92 PARP1 (0.50) MKNK1MKNK2NFE2L2NNMTPARP1
Adipic Acid SCHEMBL3220731 0.84 TSHR (0.50) MKNK1MKNK2NFE2L2SMN1; SMN2KMT2A
SCHEMBL23846347 0.84 MKNK1 (0.59) MKNK1MKNK2NNMTPARP1
SCHEMBL7837115 0.83 NFE2L2 (0.46) NFE2L2KMT2AHSD11B1NPC1RAB9A
SCHEMBL11379714 0.83 NFE2L2 (0.49) NFE2L2SMN1; SMN2KMT2AHTTHSD11B1
SCHEMBL1804232 0.82 PARP1 (0.47) NNMTPARP1SMN1; SMN2TDP1NPC1
SCHEMBL2128609 0.82 PARP1 (0.52) MKNK1MKNK2NNMTPARP1SMN1; SMN2
SCHEMBL1003845 0.82 MEN1 (0.53) PARP1SMN1; SMN2KMT2ATDP1NPC1
SCHEMBL9420260 0.81 NFE2L2 (0.55) NFE2L2SMN1; SMN2KMT2AHTTHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107102082-B Method for determining residual quantity of amitraz and metabolite thereof in royal jelly by liquid chromatography-mass spectrometry/mass spectrometry 浙江省检验检疫科学技术研究院 2019-12-17 CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-2292625-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2013-12-25 EP claimed
EP-1648874-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-10-05 EP claimed
EP-1846035-B1 COMBINATION THERAPY XENON PHARMACEUTICALS INC (CA) 2011-09-21 EP claimed
US-20100222330-A1 New Compounds BIOVITRUM AB (SE) 2010-09-02 US claimed
US-20100056460-A1 COMBINATION OF ORGANIC COMPOUNDS ALI MOHAMMED A 2010-03-04 US claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
US-7572787-B2 Substituted naphthalene sulfonamides BIOVITRUM AB (SE) 2009-08-11 US claimed
US-20090131447-A1 COMBINATION THERAPY XENON PHARMACEUTICALS INC. (CA) 2009-05-21 US claimed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 WO claimed
US-20020025977-A1 N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives NEUROGEN CORPORATION 2002-02-28 US claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed
EP-0550557-B1 DETERGENT CONTAINING ALKYL SULFATE AND POLYHYDROXY FATTY ACID AMIDE SURFACTANTS PROCTER & GAMBLE (US) 1996-03-20 EP claimed
EP-0670874-A1 LOW SUDSING POLYHYDROXY FATTY ACID AMIDE DETERGENTS THE PROCTER & GAMBLE COMPANY (US) 1995-09-13 EP claimed
WO-1994012597-A1 LOW SUDSING POLYHYDROXY FATTY ACID AMIDE DETERGENTS THE PROCTER & GAMBLE COMPANY (US) 1994-06-09 WO claimed
US-4942232-A FOR PRINTING AND DYEING CELLULOSE FIBERS BASF AKTIENGESELLSCHAFT (DE) 1990-07-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025977-A1 N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives CRHR1, CRHR2, HTR2C MKNK1 3664/4885MKNK2 3810/4885NFE2L2 1289/4885
US-20100056460-A1 COMBINATION OF ORGANIC COMPOUNDS REN, IAPP, ACE MKNK1 1643/4885MKNK2 2190/4885NFE2L2 2111/4885
US-20090131447-A1 COMBINATION THERAPY SCD, SCD5, ARG1 MKNK1 3611/4885MKNK2 3520/4885NFE2L2 4125/4885
US-20100222330-A1 New Compounds SULT2A1, GPR119, STS MKNK1 2907/4885MKNK2 2301/4885NFE2L2 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.